Striatal Dopamine Transporter Alterations in ADHD: Pathophysiology or Adaptation to Psychostimulants? A Meta-Analysis
Publication: American Journal of Psychiatry
Abstract
Background:
Striatal dopamine transporter abnormalities are thought to underlie the pathophysiology and psychostimulant treatment of attention deficit hyperactivity disorder (ADHD). However, individual studies using single photon emission tomography (SPECT) or positron emission tomography (PET) have yielded inconsistent results, i.e., both high and low striatal dopamine transporter levels.
Method:
Nine SPECT and PET studies investigating striatal dopamine transporter density in ADHD patients (N=169) and age-, gender-, and IQ-matched healthy comparison subjects (N=173) were included in a quantitative meta-analysis. Binding potentials in the striatum and demographic, clinical, and methodological variables were extracted from each publication or obtained directly from authors. Hedges' g was used as a measure of effect size in an analysis using Comprehensive Meta-Analysis software. Publication bias was assessed with funnel plots and Egger's intercept. Heterogeneity was addressed with the Q statistic and I2 index.
Results:
Striatal dopamine transporter density was 14% higher on average in the ADHD group than in the healthy comparison group. However, heterogeneity across studies was large and statistically significant. Meta-regression analyses showed that the percentage of subjects without exposure to psychostimulants was negatively correlated with dopamine transporter density; density was higher in patients with previous medication exposure and lower in medication-naive patients. There was no moderating effect for age, comorbidity, gender, year of publication, or imaging technique. There was no publication bias, and sensitivity analysis confirmed robustness of the results.
Conclusions:
Striatal dopamine transporter density in ADHD appears to depend on previous psychostimulant exposure, with lower density in drug-naive subjects and higher density in previously medicated patients.
Attention deficit hyperactivity disorder (ADHD) is characterized by age-inappropriate symptoms of inattention, impulsiveness, and hyperactivity (1). It affects 3%–8% of school-age children, disrupting academic and social development, and persists into adulthood in 65% of those affected, amounting to 4% of the adult population (2, 3). Cognitively, children and adults with ADHD have deficits in late-developing cognitive functions, most prominently inhibition, attention, motivation, and timing functions that are known to be mediated by late-developing frontostriatal and cerebellar networks (4, 5).
The biological origins of ADHD are complicated by heterogeneous clinical symptoms, comorbidity (in approximately 65% of the cases) with other disorders (conduct, mood, and anxiety disorders and Tourette's syndrome), and exacerbation by adverse environments and psychosocial events (6). The last two decades of structural and functional imaging studies have shown that ADHD is associated with deficits in the structure, functioning, and connectivity of frontostriatal, parietotemporal, and frontocerebellar networks (5, 7, 8). A recent meta-analysis of all structural voxel-based morphometry studies in ADHD, however, showed that the most consistent deficit is low gray matter volume in the basal ganglia (9).
Studies using positron emission tomography (PET) and single photon emission tomography (SPECT), conducted mostly in adults with the disorder, have focused predominantly on the neurotransmitter dopamine, given that it is known to have a central role in the regulation of psychomotor activity, motivation, and the frontostriatal-mediated inhibitory, timing, and attention functions that are compromised in the disorder (10). The focus on striatal dopamine has been reinforced by structural, functional, and neurochemical imaging findings of striatal deficits (5, 7–9). The striatum receives dense ascending projections from the mesencephalic dopamine neurons of the substantia nigra and ventral tegmental area (11). The interest in striatal dopamine was further heightened by the fact that the striatal dopamine transporter is the main target for one of the most effective treatments of ADHD, methylphenidate (12–15), which has been shown to block about 70% of striatal dopamine transporters (16), leading to enhanced striatal dopamine availability (12). Last, dopamine receptor and transporter genotypes have been associated with the disorder (for a meta-analysis, see reference 13).
The membrane-bound presynaptic dopamine active transporter plays a key role in regulating the dopamine content in the synaptic cleft by removing the dopamine molecules from the synaptic cleft and returning them to the presynaptic cell (16a [available here]). Dopamine transporters are localized in dopaminergic axons, with the highest levels in the striatum and olfactory tubercle and much lower levels in the amygdala, hypothalamus, hippocampus, thalamic nuclei, and neocortex (14). Because striatal dopamine transporters are located exclusively on dopamine-synthesizing neurons, the measurement of striatal dopamine transporter density is a specific marker of presynaptic dopaminergic neuron integrity (15). It is possible to simultaneously visualize and quantify dopamine transporter binding by using radioligands and SPECT or PET (Figure 1).
FIGURE 1. Simplified Diagram of a Striatal Dopaminergic Synapsea
a On the presynaptic side, potential markers for imaging of the integrity of dopaminergic neurons are shown. A measure of dopamine-synthesizing capacity is provided by [18F]DOPA PET and [11C]DOPA PET. In the case of [18F]DOPA PET, the radiotracer is taken up in the dopaminergic neuron via an l-amino acid transporter and is then decarboxylated to [18F]fluorodopamine by aromatic l-amino acid decarboxylase (AAADC) and temporarily stored in vesicles (vescicular monoamine transporter, type 2) within the nerve terminals. In humans, [11C]dihydroxytetrabenazine ([11C]DTBZ) is a commonly used marker for the vescicular monoamine transporter 2, which provides an index of monoamine presynaptic terminal density. Substituted (nor)phenyltropanes ([123I]FP-CIT, [123I]β-CIT, [11C]PE2I, [11C]CFT, and [99mTc]TRODAT) are frequently used PET and SPECT tracers for imaging of dopamine active transporters in humans. Striatal density of dopamine active transporters provides another measure of the density of dopaminergic presynaptic terminals or innervation into the striatum. Finally, commonly used radiotracers for D2/3 receptors are substituted benzamides ([123I]IBZM, [11C]raclopride, and [18F]fallypride) and are used to address postsynaptic functioning. For convenience, only D2 receptors are shown on the postsynaptic cell.
The findings on dopamine transporter levels in the striatum of patients with ADHD relative to those of comparison subjects have been inconsistent. While several of the earlier studies showed higher dopamine transporter levels in ADHD patients (16), some showed no difference (17) and others indicated lower dopamine transporter levels in ADHD (10). Reasons for the discrepancies could be 1) differences in radiotracers or the methods used, 2) differences in patients' characteristics, including medication history, comorbid conditions, and age, and 3) differences in study group sizes. One of the most compelling confounds is psychostimulant medication, given the known acute effect of psychostimulants of modulating striatal dopamine transporters (12). A number of critical reviews have addressed dopamine transporter alterations in ADHD (6, 18–21); however, to our knowledge, no formal meta-analysis has ever tested the magnitude of these abnormalities while controlling for the aforementioned confounds, particularly medication effects.
In this meta-analysis of PET and SPECT studies, we aimed to examine the meta-analytic evidence for a consistent alteration of striatal dopamine transporter density across studies. In addition, we aimed to assess the effect of medication history and a number of other moderator variables, including age, comorbid conditions, gender, and publication year.
Method
Selection Procedures
A systematic search strategy was used to identify relevant studies. First, we carried out a search of PubMed, Science Direct, and Scopus to identify putative studies of striatal dopamine transporters in ADHD subjects. We used the following search terms: “DAT,” “dopamine transporter,” “ADHD,” “PET,” and “SPECT.” In a second step, the reference lists of the articles included in the review were manually checked for relevant studies not identified by computerized literature searching. Next, the corresponding authors were contacted by e-mail with a request for any details not included in the original manuscripts.
Studies were included if they met the following criteria: 1) were reported in an original article in a peer-reviewed journal, 2) had involved subjects affected with DSM- or ICD-defined ADHD, 3) had analyzed data for the two groups obtained with SPECT or PET techniques assessing striatal dopamine transporter density, 4) had calculated the mean and standard deviation for striatal dopamine transporter density in both groups, 5) included a healthy comparison group, and 6) did not involve a study group that overlapped with a previous group.
Recorded Variables
The recorded variables for each article included in the meta-analysis were type of radiotracer and imaging technique, gender, mean age of participants, IQ, year of publication, exposure to previous stimulant treatments, presence of comorbid conditions, smoking status, and statistical significance of the core findings. To achieve a high standard of reporting we adopted the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines (22) and the QUOROM statement on the quality of reporting of meta-analyses (23).
Quality Assessment
Although quality assessments can be reliably conducted in meta-analyses of experimental studies, their use in observational research is controversial, with no clear consensus on rating methods or their appropriate use in analysis (24). In the present meta-analysis, we used a simple objective rating system based on a meta-analysis by Paulson and Bazemore (25). We coded each study's quality on a scale of 0 to 10, assigning 2 points each for a description of the sampling method, the presence of clearly stated inclusion criteria, assessment of ethnic diversity, assessment of educational diversity, and a comprehensive description of the main outcome measure. Studies that included these features thus received a higher quality rating. Because evidence about the validity of quality ratings in observational research is lacking, we adopted the MOOSE (meta-analysis of observational studies in epidemiology) approach of broadly including studies and using sensitivity analysis to determine incremental effects of lower-quality studies (26).
Statistical Analysis
Data were analyzed by using Comprehensive Meta-Analysis software, version 2 (Biostat, Englewood, N.J.). The primary outcome was striatal dopamine transporter binding in the patients and the comparison group. To measure effect size, we adopted Hedges' g, i.e., the difference between the means of the patient and comparison groups, divided by the standard deviation and weighted for group size in order to correct for bias from small groups (27). This metric is computed by using the square root of the mean square error from the analysis of variance testing for differences between the two groups (27), along with the 95% confidence interval (CI).
Subanalyses were conducted to assess the impact of categorical moderator variables. Meta-regression analyses were used to test the influence of continuous moderator variables: year of publication, age of participants, and gender (percentage of females). The slope of meta-regression, i.e., the β coefficient, either direct (+) or inverse (–), of the regression line indicates the strength of the relationship between moderator and outcome. To limit the risk of false positive (type I) errors arising from multiple comparisons, we adjusted p<0.05 by dividing α by the number of meta-regressions, i.e., 7.
In general, random-effects models are more conservative than fixed-effect models and appear to better address heterogeneity among studies and study groups, allowing for greater flexibility in parsing effect size variability. Moreover, they are less influenced by extreme variations in group size (28). Because the studies in this meta-analysis were characterized by heterogeneity, random-effects models were used. Heterogeneity among study point estimates was assessed with the Q statistic, and the magnitude of heterogeneity was evaluated with the I2 index (29). Studies with negative results are less likely to be published than studies with statistically significant results. The possibility of a publication bias in the present study was examined by visually inspecting funnel plots and applying the regression intercept of Egger et al. (30). In this way we assessed whether there was a tendency for selective publication of studies based on the nature and direction of their results. In addition, we used the fail-safe procedure (31) to generate the number of unpublished studies that would be needed to move estimates to a nonsignificant threshold. To assess the robustness of the results, we performed sensitivity analyses by sequentially removing each study and rerunning the analysis.
Results
Studies Found
The combined search strategies yielded a total of 59 articles, of which 38 were excluded. Of the 21 that were considered eligible, nine PET or SPECT studies published between 1999 and 2009 met our inclusion criteria and were included in the present meta-analysis (Figure 2). The overall database contained 169 subjects with ADHD (mean age=29.9 years, SD=11.8; 43% females) and 173 healthy comparison subjects (mean age=29.1 years, SD=9.3; 38% females), all well matched with respect to age, IQ, and gender (p>0.05 in all cases) (Table 1).
| N | Age (years) | |||||||
|---|---|---|---|---|---|---|---|---|
| Study and Group | Radiotracer | Technique | Total | Female | Mean | SD | ADHD Treatment Status | ADHD/Comparison Ratio of Dopamine Transporters |
| Dougherty et al., 1999 (16) | [123I]altropane | SPECT | Drug-free | 1.70a | ||||
| ADHD | 6 | 4 | 41.33 | 4.46 | ||||
| Comparison | 30 | — | 40.80 | —b | ||||
| van Dyck et al., 2002 (17) | [123I]β-CIT | SPECT | 8 drug-naive, 1 drug-free | 1.00 | ||||
| ADHD | 9 | 3 | 41 | 11 | ||||
| Comparison | 9 | 3 | 41 | 11 | ||||
| Cheon et al., 2004 (32) | [123I]IPT | SPECT | Drug-naive | 1.51a | ||||
| ADHD | 9 | 2 | 9.67 | 2.12 | ||||
| Comparison | 6 | — | 10.33 | 2.88 | ||||
| Jucaite et al., 2005 (33) | [11C]PE2I | PET | 9 drug-naive, 3 drug-free | 1.08 | ||||
| ADHD | 12 | 0 | 13.8 | 1.2 | ||||
| Comparison | 10 | 0 | 29.5 | 5.8 | ||||
| la Fougere et al., 2006 (34) | [99mTc]TRODAT-1 | SPECT | Drug-free | 1.16a | ||||
| ADHD | 22 | 11 | 39.1 | 10.2 | ||||
| Comparison | 14 | 6 | —c | |||||
| Larisch et al., 2006 (35) | [123I]FP-CIT | SPECT | Drug-naive | 1.06a | ||||
| ADHD | 20 | 11 | 35 | 7 | ||||
| Comparison | 20 | 11 | 32 | 8 | ||||
| Spencer et al., 2007 (36) | [11C]altropane | PET | Drug-naive | 1.15a | ||||
| ADHD | 21 | 7 | 34.4 | 9.2 | ||||
| Comparison | 26 | 15 | 27.4 | 7.6 | ||||
| Volkow et al., 2009 (10) | [11C]cocaine | PET | Drug-naive | 0.80a | ||||
| ADHD | 53 | 26 | 32 | 8 | ||||
| Comparison | 44 | 14 | 31 | 6 | ||||
| Hesse et al., 2009 (37) | [123I]FP-CIT | SPECT | Drug-naive | 0.81a | ||||
| ADHD | 17d | 9 | 32 | 8 | ||||
| Comparison | 14 | 6 | 32 | 9 | ||||
a
Statistically significant.
b
Age range=21–60.
c
Age range=21–63.
d
With psychiatric or neurological comorbidity.
Dopamine Transporter Density in Striatum
Two out of the nine studies showed no significant difference in striatal dopamine transporter density between the ADHD and comparison groups (17, 33), while five studies showed higher dopamine transporter density in the ADHD group (16, 32, 34–36) and two studies showed lower dopamine transporter density in ADHD (10, 37). The pooled meta-analysis indicated consistent statistical evidence for greater dopamine transporter density in the ADHD group than in the comparison group in the whole striatum (Figure 3), although the magnitude of the effect size was small. The ratio of striatal dopamine transporter density in the ADHD group to the density in the comparison group ranged from 0.80 to 1.70 (Table 1), with an average value of 1.14. No laterality effect was detected.
Effect of Moderators
The type of imaging technique (PET or SPECT) did not influence the meta-analytical results (Q=2.74, p=0.61). Meta-regression analyses revealed no significant effects on the findings for gender (β=–0.41, 95% CI=–0.53 to 1.35, z=0.86, p=0.39), year of publication (β=–0.00, 95% CI=–0.08 to 0.08, z=–0.09, p=0.93), or age of the patients (β=0.02, 95% CI=–0.01 to 0.04, z=1.09, p=0.28) or the healthy comparison subjects (β=–0.01, 95% CI=–0.05 to 0.03, z=–0.68, p=0.50). However, within the comparison group, when age was treated as a categorical variable and the studies were divided into those whose comparison group had a mean age above 40 years (39 subjects) and studies with comparison subjects having a mean age below 30 years (42 subjects), we detected a nearly significant difference in dopamine transporter density, with a lower density in the older group (Hedges' g=–0.03, p=0.07). The percentage of ADHD subjects without previous psychostimulant exposure had a significant negative effect on the Hedges' g value for striatal dopamine transporter levels, in that lower and negative effect sizes were detected in studies involving drug-naive ADHD patients (Figure 4). Thus, lower dopamine transporter levels were associated with the absence of medication exposure, while higher dopamine transporter levels were associated with a history of medication. Post hoc analyses confirmed higher dopamine transporter levels (Hedges' g=1.56) for the medication-history subgroup and lower dopamine transporter levels for the medication-naive subgroup (Hedges' g=–0.10) relative to the comparison subjects. The modulating effect of stimulant exposure accounted for 48% of the overall variance (Q=29.73, p<0.001). Finally, all of the studies but one excluded individuals with comorbid psychiatric or neurological conditions from the ADHD and comparison groups.
FIGURE 4. Meta-Regression Showing Effect of Stimulant Exposure on Striatal Dopamine Transporter Density in ADHDa
a Circle size reflects the weight a study obtained in the meta-regression. Lower effect sizes were detected in studies involving drug-naive ADHD patients (β=–1.61, 95% CI=–2.19 to –1.03, z=–5.45, p<0.001).
Tests for Publication Bias and Heterogeneity and Sensitivity Analysis
Visual inspection of funnel plots revealed no evidence of publication bias. Quantitative evaluation of publication bias, as measured by the Egger intercept, indicated a nonsignificant effect (p=0.14). The fail-safe procedure estimated that 17 unpublished studies would be needed to bring the overall meta-analytic estimate to nonsignificance. According to the criteria set by Higgins and Thompson (38), the heterogeneity in the published studies was large and statistically significant (Q=61.69, p<0.001; I2=87.03). As the overall interstudy variance in effect sizes was substantial, it encouraged consideration of possible explanatory factors. Removing studies with poor quality ratings influenced the meta-analytic estimate by only 4%.
Discussion
To our knowledge, this is the first comprehensive meta-analysis addressing striatal dopamine transporter density in ADHD. Meta-analytic evidence from approximately 170 ADHD patients showed on average 14% greater density of striatal dopamine terminals in the ADHD patients than in healthy comparison subjects. However, the effect size was small and heterogeneity across studies was substantial, with a prominent effect of psychostimulant history on the findings, accounting for a substantial proportion of variance across studies. Thus, the meta-regression analysis showed that the percentage of patients without a medication history was negatively associated with dopamine transporter level, so that studies of patients receiving long-term medication showed higher dopamine transporter levels, while an absence of medication exposure was associated with lower dopamine transporter levels relative to the healthy comparison subjects. Conversely, age, gender, comorbid conditions, year of publication, and type of imaging technique had no effect on the meta-analytical estimates of striatal dopamine transporter density.
The negative correlation accounted for about half of the overall variance across studies. This suggests that the higher striatal dopamine transporter density in ADHD may be the consequence of previous treatment with stimulants and hence be the result of an adaptive response of the brain to the continuous dopamine transporter blockade with psychostimulants. This suggests that a high dopamine transporter level is not part of the key ADHD pathophysiology but is secondary to years of psychostimulant treatment and reflects an adaptive brain response to the long-term blockade of dopamine transporters by psychostimulants. This notion of an adaptation to psychostimulants is in line with the finding that methylphenidate is effective in improving clinical symptoms of ADHD in the short term but that long-term effectiveness is limited; larger doses are often required to maintain clinical effectiveness, and clinical effectiveness appears to wane after years of medication (39). A caveat is that these findings are from cross-sectional analyses, with a selection bias, and we therefore cannot infer direct causality. The theory of an adaptive response of the brain to psychostimulant medication would have to be tested directly in longitudinal imaging studies using a randomized controlled design.
The meta-analytical finding of lower dopamine transporter levels in medication-naive patients is in line with the findings from the study by Volkow et al. (10), which was one of the largest weighted studies in our meta-analysis and one of the best-controlled studies, enrolling a large number of drug-naive ADHD subjects with no comorbid psychiatric or neurological conditions and adopting stringent inclusion criteria to control for past ADHD medication and/or drug abuse history. The finding of lower striatal dopamine transporter levels in medication-naive patients is also consistent with the prominent theory that ADHD is a dysfunction of dopamine neurotransmission, with a consequent dysregulation of dopamine-modulated circuits. In particular, the striatum appears to play a prominent role in ADHD symptoms (12).
In normal development, a 6%–8% decline in striatal dopamine transporters has been observed per decade in PET and SPECT studies (40). We observed nonsignificantly lower striatal dopamine transporter levels in older relative to younger adults in the comparison group but no difference in the patients. This may hint at abnormalities in the normal age-associated striatal dopamine transporter development in ADHD patients, or it may be related to stimulant treatment.
Methylphenidate hydrochloride is one of the most efficacious treatments for ADHD, reducing symptoms in up to 70% of children (12). PET studies have shown that methylphenidate blocks dopamine transporters in the striatum in a dose-dependent fashion (41, 42), leading to an increase in extracellular striatal dopamine (43). The amount of extracellular dopamine (44) released by psychostimulants, however, is likely to depend on a combination of the blockade of dopamine transporters and the baseline rate of dopamine release, which is regulated by individual differences in dopamine cell firing and by environmental stimulation (12). Studies using [18F]DOPA or [11C]DOPA PET (43, 45) confirmed low dopamine synthesis capacity in the striatum of ADHD patients. Studies using [11C]raclopride PET to investigate postsynaptic receptor binding further showed that dopamine activity is depressed in ADHD, supporting the dopamine deficit theory of ADHD (46). Given that dopamine signals the saliency of stimuli and drives the motivation to perform goal-directed behaviors, the methylphenidate-induced amplification of the striatal dopaminergic signal would cause increased saliency perception, motivating the individual to engage and improving attention and performance (12).
Our meta-analysis finding that previous treatment with psychostimulants increased striatal dopamine transporter density in ADHD patients may seem counterintuitive, given the dopamine transporter blockade by methylphenidate. Enhanced striatal dopamine transporter density in patients receiving long-term treatment, however, could reflect a secondary adaptive brain response to the chronic striatal dopamine transporter blockade, i.e., adjustment to chronically elevated striatal dopamine availability through up-regulation of dopamine transporter levels. There is evidence in favor of this theory from a small prospective study, which showed that after 1 year of stimulant medication the striatal dopamine transporter levels of ADHD patients in fact increased (47). Furthermore, there is evidence indicating that cocaine—which is a stimulant drug that, like methylphenidate, blocks dopamine transporters—not only blocks the acute regulatory effect of the dopamine transporter on synaptic dopamine levels but also may exert the opposite effect: insertion of dopamine transporters from the endosomic recycling pool into the plasma membrane (48). In rhesus monkeys, chronic administration of cocaine up-regulates striatal dopamine transporter expression, which persists for more than 30 days after cocaine withdrawal (48). High dopamine transporter expression has also been shown in postmortem analyses of brain tissue from human cocaine addicts, and synaptosomes prepared from this tissue exhibit greater dopamine uptake than synaptosomes from age-matched cocaine-naive individuals (48).
Methylphenidate-associated changes have also been observed in brain function and structure. Functional MRI studies in patients with ADHD have shown that single and long-term doses of methylphenidate up-regulate and normalize typically low frontostriatal brain activation (49–54). Because striatal dopamine transporters are located exclusively on dopamine-synthesizing neurons, their measurement is a specific marker of dopaminergic neuron integrity in the basal ganglia. The notion of adaptive brain changes in response to long-term psychostimulant treatment is also in line with the results of several structural imaging studies showing that patients with ADHD receiving long-term medication have more normal structure and morphometry in the basal ganglia than medication-naive patients (55, 56). These findings are further confirmed by a recent meta-analysis of whole-brain structural imaging studies, which showed that the lower basal ganglia gray matter volume in ADHD patients, relative to that in comparison subjects, is dependent on long-term medication (9). The percentage of patients receiving long-term medication was linearly associated with basal ganglia size, such that studies in which more than 70% of the patients were medicated did not show striatal abnormalities, while the greatest deficits were observed in studies of medication-naive patients.
It is, however, also possible that lower dopamine transporter density and lower dopamine release in medication-naive ADHD patients reflect prefrontal pathology, well demonstrated in neuroimaging results for ADHD (5), since frontostriatal glutamatergic circuits regulate striatal dopamine release.
The present study has several limitations. The meta-regression finding of an association between medication and dopamine transporter density is limited by the cross-sectional nature of the analysis, and causality of the regression findings needs to be established in longitudinal prospective studies using a randomized controlled design. It has been suggested that high heterogeneity across studies may be due to differing dopamine transporter sensitivity across the different radiotracers employed. For example, there is evidence that the specific-to-nonspecific ratio of labeled cocaine is relatively low and that this radioligand may occupy binding sites other than those occupied by FP-CIT, altropane, TRODAT-1, and IPT (57). Furthermore, dopamine transporter binding may be influenced by a complex network of interactions with other receptors or neurotransmitters. For example, there is recent evidence that norepinephrine transporters contribute to the pathophysiology of ADHD, with norepinephrine transporter blockade in frontal regions underlying some of the therapeutic effects of methylphenidate (58). However, while methylphenidate enhances both norepinephrine and dopamine in prefrontal brain regions, where it blocks both the relatively densely distributed norepinephrine transporters and the less densely distributed dopamine transporters (58), in the basal ganglia methylphenidate has minimal effects on norepinephrine levels, since the norepinephrine transporter density is vanishingly low (6). Other studies have found that presynaptic D2 autoreceptor activation, normally constraining dopamine action at synapses, regulates dopamine transporter activity that modulates synaptic dopamine homeostasis (59). The picture is further complicated by a potential interplay between dopamine transporter functioning and nicotinic neurotransmission at the presynaptic level (60). Finally, there is recent evidence suggesting that the ADHD diagnostic category comprises multiple entities with different underlying pathophysiologies and abnormalities of neurotransmitter profiles (61). In particular, children with the combined/hyperactive subtype of ADHD show a higher frequency of conduct disorder and good response to treatment, are exposed to more moderate stress during their mothers' pregnancies, and have a higher frequency of the L genotype for a polymorphic region of the serotonin transporter gene, as compared to children with the inattentive ADHD subtype (61). On the basis of animal studies showing dopamine transporter differences in the pathophysiology of the two subtypes, it is possible to speculate that treatment with methylphenidate might normalize abnormal dopamine transporter levels more effectively in the combined subtype (62).
The meta-analysis and meta-regression analysis show that striatal dopamine transporter levels in ADHD depend on chronic psychostimulant treatment, so that medication-naive patients have low striatal dopamine transporter levels, whereas patients receiving long-term medication have high levels. Consequently, the previously reported high dopamine transporter density in ADHD patients may potentially represent up-regulation secondary to chronic administration of psychostimulants, rather than primary pathophysiology of ADHD. Future prospective studies using randomized controlled trials in large groups of drug-naive individuals with ADHD will be needed to definitively clarify the long-term effect of psychostimulants on striatal dopaminergic neurotransmission.
Footnote
Received June 20, 2011; revisions received Sept. 25 and Oct. 22, 2011; accepted Oct. 27, 2011
Supplementary Material
File (appi.ajp.2011.11060940_ds001.pdf)
- View/Download
- 60.89 KB
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC, APA, 1994
2.
Polanczyk G, Moffitt TE, Arseneault L, Cannon M, Ambler A, Keefe RS, Houts R, Odgers CL, Caspi A: Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. Arch Gen Psychiatry 2010; 67:328–338
3.
Biederman J, Petty C, Faraone SV, Hirshfeld-Becker DR, Henin A, Rauf A, Scott M, Pollack M, Rosenbaum JF: Childhood antecedents to panic disorder in referred and nonreferred adults. J Child Adolesc Psychopharmacol 2005; 15:549–561
4.
Cubillo A, Rubia K: Structural and functional brain imaging in adult attention-deficit/hyperactivity disorder. Expert Rev Neurother 2010; 10:603–620
5.
Rubia K: “Cool” inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus “hot” ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review. Biol Psychiatry 2011; 69(12):e69–87
6.
Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57:1397–1409
7.
Konrad K, Eickhoff SB: Is the ADHD brain wired differently? a review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp 2010; 31:904–916
8.
Valera EM, Faraone SV, Murray KE, Seidman LJ: Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61:1361–1369
9.
Nakao T, Radua J, Rubia K, Mataix-Cols D: Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011; 168:1154–1163
10.
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM: Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009; 302:1084–1091
11.
Holt DJ, Graybiel AM, Saper CB: Neurochemical architecture of the human striatum. J Comp Neurol 1997; 384:1–25
12.
Volkow ND, Wang GJ, Fowler JS, Ding YS: Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57:1410–1415
13.
Gizer IR, Ficks C, Waldman ID: Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009; 126:51–90
14.
Piccini PP: Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003; 18(suppl 7):S3–S8
15.
Meisenzahl EM, Schmitt GJ, Scheuerecker J, Moller HJ: The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry 2007; 19:337–345
16.
Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ: Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354:2132–2133
17.
van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB: Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 2002; 159:309–312
18.
Zimmer L: Positron emission tomography neuroimaging for a better understanding of the biology of ADHD. Neuropharmacology 2009; 57:601–607
19.
Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, Fischman AJ: In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 2005; 57:1293–1300
20.
Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M: The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2003; 27:605–613
21.
van der Kooij MA, Glennon JC: Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev 2007; 31:597–618
22.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535
23.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF QUOROM group: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Br J Surg 2000; 87:1448–1454
24.
Juni P, Witschi A, Bloch R, Egger M: The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282:1054–1060
25.
Paulson JF, Bazemore SD: Prenatal and postpartum depression in fathers and its association with maternal depression: a meta-analysis. JAMA 2010; 303:1961–1969
26.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group: Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283:2008–2012
27.
Hedges L, Holkin I: Statistical Methods for Meta-Analysis. New York, Academic, 1985
28.
Cooper H, Hedges L, Valentine J (eds): Handbook of Research Synthesis and Meta-Analysis. New York, Russell Sage Foundation, 2009
29.
Lipsey M, Wilson D: Practical Meta-Analysis. Thousand Oaks, Calif, Sage Publications, 2000
30.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629–634
31.
Orwin R: A fail-safe N for effect size in meta-analysis. J Edu Stat 1983; 8:157–159
32.
Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD: Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Res 2004; 130:85–95
33.
Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L: Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005; 57:229–238
34.
la Fougere C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, Koch W, Hahn K, Tatsch K, Dresel S: Value of 99mTc-TRODAT-1. SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun 2006; 27:733–737
35.
Larisch R, Sitte W, Antke C, Nikolaus S, Franz M, Tress W, Müller H-W: Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun 2006; 27:267–270
36.
Spencer TJ, Biederman J, Madras BK, Dougherty DD, Bonab AA, Livni E, Meltzer PC, Martin J, Rauch S, Fischman AJ: Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol Psychiatry 2007; 62:1059–1061
37.
Hesse S, Ballaschke O, Barthel H, Sabri O: Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res 2009; 171:120–128
38.
Higgins J, Thompson S: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539–1558
39.
Hazell P: The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder. Curr Opin Psychiatry 2011; 24:286–290
40.
Varrone A, Halldin C: Molecular imaging of the dopamine transporter. J Nucl Med 2010; 51:1331–1334
41.
Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE: Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003; 34:77–80
42.
Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH: Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 2005; 255:428–431
43.
Ludolph AG, Kassubek J, Schmeck K, Glaser C, Wunderlich A, Buck AK, Reske SN, Fegert JM, Mottaghy FM: Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study. Neuroimage 2008; 41:718–727
44.
Volkow N, Wang GJ, Fowler J, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21(2):RC121
45.
Forssberg H, Fernell E, Waters S, Waters N, Tedroff J: Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder. Behav Brain Funct 2006; 2:40
46.
Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM: Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64:932–940
47.
Wang G-J, Volkow N, Wigal T, Kollins S, Newcorn J, Telang F, Logan J, Wong C, Fowler JS, Swanson JM: Chronic treatment with methylphenidate increases dopamine transporter density in patients with attention deficit hyperactive disorder. J Nucl Med 2009; 50(suppl 2):1283
48.
Schmitt KC, Reith ME: Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann NY Acad Sci 2010; 1187:316–340
49.
Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E: Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology 2009; 57:640–652
50.
Rubia K, Halari R, Cubillo A, Smith AB, Mohammad AM, Brammer M, Taylor E: Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naive boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 2011; 36:1575–1586
51.
Rubia K, Halari R, Mohammad AM, Taylor E, Brammer M: Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit hyperactivity disorder. Biol Psychiatry 2011; 70:255–262
52.
Rubia K, Halari R, Christakou A, Taylor E: Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate. Philos Trans R Soc Lond B Biol Sci 2009; 364:1919–1931
53.
Shafritz KM, Marchione KE, Gore JC, Shaywitz SE, Shaywitz BA: The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Am J Psychiatry 2004; 161:1990–1997
54.
Bush G: Neuroimaging of attention deficit hyperactivity disorder: can new imaging findings be integrated in clinical practice? Child Adolesc Psychiatr Clin N Am 2008; 17:385–404
55.
Sobel LJ, Bansal R, Maia TV, Sanchez J, Mazzone L, Durkin K, Liu J, Hao X, Ivanov I, Miller A, Greenhill LL, Peterson BS: Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder. Am J Psychiatry 2010; 167:977–986
56.
Semrud-Clikeman M, Pliszka SR, Lancaster J, Liotti M: Volumetric MRI differences in treatment-naive vs chronically treated children with ADHD. Neurology 2006; 67:1023–1027
57.
Krause J: SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 2008; 8:611–625
58.
Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS: Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010; 68:854–860
59.
Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, Galli A: Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 2010; 30:6048–6057
60.
Weiss S, Tzavara ET, Davis RJ, Nomikos GG, McIntosh JM, Giros B, Martres MP: Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice. Neuropharmacology 2007; 52:1496–1508
61.
Grizenko N, Paci M, Joober R: Is the inattentive subtype of ADHD different from the combined/hyperactive subtype? J Atten Disord 2010; 13:649–657
62.
Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI, Becker A, Rothenberger A, Bock N: Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 2010; 167:1183–1191
Information & Authors
Information
Published In
History
Received: 20 June 2011
Revision received: 25 September 2011
Revision received: 22 October 2011
Accepted: 27 October 2011
Published online: 1 March 2012
Published in print: March 2012
Authors
Funding Information
Dr. Rubia has received speakers' honoraria from Eli Lilly, Medice, Novartis, and Shire. Dr. Rossi served as principal investigator in Shire study SPD503-316 in 2011 and as an investigator in Eli Lilly study B4Z-IT- LICY in 2006. The other authors report no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).